



MEDICAL THERAPIES AND PHARMACOLOGY

SHORT-CONTACT TOPICAL CALCIPOTRIENE FOAM AND FLUOROURACIL CREAM AFTER CRYOTHERAPY FOR ACTINIC KERATOSIS

A. Moore⁽¹⁾ - M. Nguyen⁽¹⁾

Arlington Research Center, Research, Arlington Texas, United States⁽¹⁾

Introduction: Treatments for actinic keratoses (AKs), precursors to squamous cell carcinoma, include cryotherapy (LN2) and topical 5-fluorouracil (5-FU). Due to 5-FU irritation, short-contact 5-FU has been reported. Recent research suggests that topical Vitamin D may also be efficacious AK treatment.

Objective: This retrospective study evaluates efficacy and safety of short-contact topical calcipotriene foam (Vit D3) and 5-FU 1% cream (5-FU) after LN2 for AK treatment compared to short-contact Vit D3 after LN2, short-contact 5-FU after LN2, and LN2.

Materials and Methods: Retrospective data between 2016 and 2018 was collected on 50 patients with AKs treated with short-contact Vit D3 + 5-FU after LN2, 5-FU after LN2, and with LN2, respectively, and on 25 patients with AKs treated with short-contact Vit D3 after LN2 treated. Lesion counts of AK's were assessed on the face, upper or lower extremities, scalp, chest, and back at baseline, 51-100 days, 101-200 days, and 201-300 days. An analysis of covariance (ANCOVA) model with terms for treatment and baseline lesion count as covariate was used to compare post-treatment lesion counts between treatment groups, estimated at 95% confidence intervals.

Results: After adjusting for imbalances in baseline count, statistically significant reductions in AKs occurred with short-contact 5-FU +Vit D3 treatment after LN2 by 101-200 days, and also with short-contact Vit D3 after LN2 and short-contact 5-FU after LN2 by 201-300 days, respectively, compared to LN2.

Conclusions: Addition of topical Vit D3 to short-contact 5-FU after LN2 causes statistically significant reductions in AKs by 101-200 days and may result in improved long-term outcomes for patients with AKs. Larger prospective, randomized series must be performed to confirm increased efficacy and safety.





International League of Dermatological Societies Skin Health for the World

